Lakhani, Nehal J.

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Johnson, M., El-Khoueiry, A., Hafez, N., Lakhani, N., Mamdani, H., Rodon, J., Sanborn, R. E., Garcia-Corbacho, J., Boni, V., Stroh, M., et al. (2021) · Clinical Cancer Research

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 72

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Subbiah, V., Chawla, S. P., Conley, A. P., Wilky, B. A., Tolcher, A., Lakhani, N. J., Berz, D., Andrianov, V., Crago, W., Holcomb, M., et al. (2023) · Clinical Cancer Research

Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and Treatment

Cited by 51

AVID200, first‐in‐class TGF‐beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose‐escalation study in patients with advanced solid tumors

Yap, T. A., Lakhani, N. J., Araujo, D. V., Rodon Ahnert, J., Chandana, S. R., Sharma, M., Denis, J.-F., Gruosso, T., Tremblay, G., O'Connor, M., et al. (2020) · Journal of Clinical Oncology

TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers

Cited by 26